VIARTIS

 
 

 PARKINSON'S DISEASE NEWS

 

 

 

 

 

Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail [email protected].

                                          

 

29th July 2013 - New research

PRAMIPEXOLE : EXTENDED RELEASE v IMMEDIATE RELEASE

Drug Research [2013] Jul 24 [Epub ahead of print] (M.Takanashi, Y.Shimo, T.Hatano, G.Oyama, N.Hattori) Complete abstract

Changing from Immediate release Pramipexole to Extended release Pramipexole was found to cause a reduction in Parkinson's Disease symptoms. Pramipexole, which is marketed as  Mirapex, Mirapexin, and Sifrol, is a dopamine agonist used in the treatment of Parkinson's Disease. For more information go to Mirapex and Mirapex ER.

This study aimed to evaluate the efficacy and safety of an extended-release tablet formulation of pramipexole (PPX-ER) given once daily when switched from an immediate-release tablet formulation (PPX-IR) given 3 times daily. The extended release version evens out the effect of Pramipexole. Parkinson's Disease symptom scores were reduced after 4 weeks and after 8 weeks. There was no change in the nocturnal and early morning symptoms (NEMS) score, or the Parkinson's Disease Sleep Scale (PDSS-2). Nearly two thirds of patients and caregivers preferred the extended release version. For a printable version of this article click here. For more news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articles are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 
©2006-2013  Viartis
 
2015-08-21 21:02:09
 
[email protected]